loading

INVITRO INTERNATIONAL POSTS 3RD CONSECUTIVE PROFITABLE QUARTER

Company also receives Corrositex endorsement from government sponsored science panel
W. Richard Ulmer
(800) 2-INVITRO
INVITRO INTERNATIONAL
Irvine

Glenn Bertolini
(619) 525-0800
COMPASS POINT GROUP, INC.

Irvine, CA August 3, 1999 — Invitro International (OTC IVRO) announced that its third quarter ended June 30, 1999 produced sales revenues of $150,060 and net income of $5,700. Fiscal 1999 year to date sales of nearly $479,000 are 17½% ahead of 1998 with the income total of $49,083 comparing favorably to a loss of $184,073 in the prior year.

In other important company news, InVitro announced that it had received an endorsement for its product Corrositex from a federally appointed panel of scientists (National Institute of Environmental Health Sciences) for use in evaluating potential skin corrosivity and irritation from chemicals and chemical formulations. Corrositex is the first such non-animal test method product endorsed by a U.S. government body. The panel review suggests that Corrositex testing can fully replace the use of animals for testing corrosiveness and irritation in some cases, while in others a tiered testing approach may be employed, thus having the potential to reduce considerably the numbers of laboratory animals used. This approach also has the potential to lower industry testing costs. IVRO President & CEO, W. Richard Ulmer, said “We are delighted and proud that our Corrositex test method can lead the way to lowering chemical, cosmetic, and other industry costs, save these companies time in their new product development cycles, and offers a bit of a good feeling for everyone when fewer animals are used in testing overall. We know that over 2000 new chemicals are introduced each year, and of course there are even more new cosmetic and over the counter personal products; our task now is to use our added new credibility to inform these manufacturers of how InVitro’s several non-animal test methods can help them.”



CONDENSED
CONSOLIDATED STATEMENT OF OPERATIONS


  Three months ended
June 30

Nine months ended June 30

 

1999


1998


1999


1998

Revenues

150,060


138,557


478,711


407,574

Costs and expenses

152,074


230,170


446,914


593,148

Income (loss) from operations

(2014)


(36,000)


31,797


(185,574)

Other income (loss)

7,751


950


17,286


1,501

Net income (loss)

5,737


(90,663)


49,083


(184,073)

Income (loss) per common share

0.0004


(0.0100)


0.0034


(0.0131)

Weighted average common
shares outstanding

14,453,300


14,023,300


14,453,300


14,023,300

 



CONDENSED
CONSOLIDATED BALANCE SHEET

     

June 30, 1999


Sep 30, 1998

 

(UNAUDITED)

 
Cash, cash equivalents
and marketable securities

75,050


59,960

Other current assets    

223,302


268,571

Total current assets    

298.352


328,531

Noncurrent assets    

203,641


154,479

Total assets    

501,993


483.010

Current liabilities    

21,678


54,856

Shareholders’ equity    

480,315


428,154

Total liabilities and equity
   

501,993


483,010

Posted on Categories News

Leave a Reply

Your email address will not be published. Required fields are marked *